Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesda...
Protara Therapeutics, Inc. (TARA)
Company Research
Source: Yahoo! Finance
company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 trial assessing TARA-002, the Company's investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs). The live event and accompanying slides can be accessed by visiting https://protara-therapeutics-update-call.open-exchange.net/registration , or via the Events and Presentations section of the Company's website: https://ir.protaratx.com . A replay of the webcast will be archived for a limited time following the event. About TARA-002 in LMs TARA-002 is an investigational, genetically distinct strain of streptococcus pyogenes that is inactivated while retaining its immune-stimulating properties. It was developed from the same master c
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Announces Pricing of $75 Million Public OfferingGlobeNewswire
- Protara Announces Proposed Public Offering [Yahoo! Finance]Yahoo! Finance
- Protara Announces Proposed Public OfferingGlobeNewswire
- Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]Seeking Alpha
- Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
TARA
Earnings
- 11/10/25 - Beat
TARA
Sec Filings
- 12/4/25 - Form 424B5
- 12/3/25 - Form 8-K
- 11/19/25 - Form 8-K
- TARA's page on the SEC website